Trials / Completed

CompletedNCT00540072

Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: —

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
Sex: All
Age: 18 Years
Healthy volunteers: —

Summary

A COMPARASON OF CIDECIN™ (DAPTOMYCIN) TO ROCEPHIN® (CEFTRIAXONE) IN THE TREATMENT OF MODERATE TO SEVERE COMMUNITY-ACQUIRED ACUTE BACTERIAL PNEUMONIA DUE TO S. PNEUMONIAE

Conditions

Pneumonia, Bacterial

Interventions

Type	Name	Description
DRUG	daptomycin

Timeline

Start date: 2001-07-30
Primary completion: 2002-02-27
Completion: 2002-02-27
First posted: 2007-10-05
Last updated: 2019-11-14

Source: ClinicalTrials.gov record NCT00540072. Inclusion in this directory is not an endorsement.